tirzepatide mastery course
Unit 9 of 12

Safety & Monitoring

gastrointestinal effects, serious risks, contraindications, and what long-term data is still missing

Understanding the Risk Profile

No drug with this level of metabolic activity comes without trade-offs. Tirzepatide's most common adverse events are gastrointestinal -- nausea, diarrhea, and vomiting -- which affect roughly 15-25% of trial participants at higher doses. More serious but rarer risks include pancreatitis, gallbladder events, and a boxed warning about thyroid C-cell tumors based on rodent data. This unit walks through the full safety profile from clinical trials and post-marketing surveillance, covers contraindications and monitoring recommendations, and identifies the gaps in long-term evidence.

Safety Profile Matrix

Explore tirzepatide's adverse event rates by dose level, severity, and organ system.

interactive safety matrix
12-26%
nausea incidence across tirzepatide doses (most common adverse event)
0.2%
pancreatitis rate, comparable to placebo (0.14 vs 0.15 per 100 patient-years)
0.6%
cholelithiasis rate with mounjaro vs 0% with placebo (rapid weight loss is a risk factor)
2 months
minimum recommended washout before planned conception (~5-day half-life)
boxed warning based on rodent data only. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors from 2-year rodent carcinogenicity studies. No cases of medullary thyroid carcinoma have been attributed to tirzepatide in human trials. However, it is contraindicated in patients with personal or family history of MTC or MEN2.

key terms for this unit

P pancreatitis serious adverse event
Inflammation of the pancreas. Reported at approximately 0.2% in tirzepatide-treated patients. Tirzepatide should be discontinued if pancreatitis is suspected. Symptoms include severe, persistent abdominal pain radiating to the back.
M mtc / men2 contraindication
Medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. Personal or family history of either condition is an absolute contraindication for tirzepatide due to the rodent C-cell tumor finding.
C cholelithiasis adverse event
Gallstone formation. Reported in 0.6% of Mounjaro-treated patients vs 0% with placebo. Rapid weight loss is an independent risk factor for gallstones regardless of method used.
A acute kidney injury serious adverse event
Kidney damage secondary to dehydration from severe GI side effects (nausea, vomiting, diarrhea), not direct nephrotoxicity. Adequate hydration and monitoring are recommended for patients with pre-existing renal impairment.
G gastroparesis contraindication
A condition of severely delayed gastric emptying. History of severe gastroparesis is a contraindication for tirzepatide because the drug may further impair gastric motility through GLP-1R-mediated mechanisms.